Covid boosters: Who needs them and how do they help? - BBC News | Canada News Media
Connect with us

Business

Covid boosters: Who needs them and how do they help? – BBC News

Published

 on


Getty Images

A panel advising the US Food and Drug Administration (FDA) is meeting to debate the need for additional doses of the Moderna and Johnson & Johnson vaccines.

The meetings on Thursday and Friday come one month after the FDA authorised Pfizer booster jabs for some Americans, including those over 65 or at higher risk of severe illness and who work in frontline jobs.

Prior to the FDA’s decision, an advisory panel at the Centers for Disease Control and Prevention (CDC) had recommended that only those above 65 and immunocompromised people between 50 and 64 receive boosters.

The Biden administration and the pharmaceutical companies involved have all offered broad support for boosters.

While the approval meant that tens of millions of US residents became eligible for a third jab, Americans across the country remain confused about boosters, who needs them and how they help.

Here’s what we know so far.

What’s the status of each vaccine?

Pfizer

Numbers: To date, more than 103 million US residents have been fully vaccinated with two Pfizer doses, while approximately 7 million have received boosters.

Efficacy: Data shows that a full dosage of the Pfizer vaccine is 88% effective in preventing hospital admission. CDC data released in mid-September shows that the vaccine’s effectiveness falls to 77% after 120 days.

Company Claim About Booster: Pfizer has been supportive of the need for boosters, with CEO Albert Bourla telling reporters that studies have shown that the vaccine’s effectiveness steadily declines to about 84% for vaccinated people four to six months after receiving their second dose.

FDA Ruling: Pfizer boosters have been approved for older adults and 50 to 64 year olds with medical conditions, as well as adults with underlying medical conditions or those who live and work in high-risk settings.

Moderna

Numbers: To date, more than 69 million people have been fully vaccinated with the Moderna vaccine, with about 1.5 million people having received Moderna booster jabs.

Efficacy: New data shows that Moderna’s vaccine was about 93% effective at reducing the risk of being admitted to hospital with Covid-19. It stays about 92% effective after 120 days.

Company Claim About Booster: Last month, Moderna said that a half-dose booster jab would boost antibodies to a higher point than the initial two shots and believes a booster will be necessary “prior to the winter season”. Currently, Moderna boosters have only been approved for certain people with weakened immune systems, such as cancer patients or transplant recipients.

FDA Ruling: The FDA has yet to decide on the safety and effectiveness of the Moderna booster shot.

Johnson & Johnson

Numbers: Nearly 15 million US residents have received a Johnson & Johnson (J&J) vaccine, which is administered in one dose. CDC data shows that only about 9,800 people have so far received J&J boosters.

Efficacy: Research shows that the J&J vaccine is 71% effective in preventing the need for hospital care. After just 28 days, the vaccine’s effectiveness falls to 68%.

Company Claim About Booster: Like Moderna, J&J has submitted a request for emergency use authorisation for its booster jab. In late September, the company said that research shows that a booster provides a 12-fold increase in antibodies and continued to climb to 12-fold higher four weeks later.

FDA Ruling: The FDA has yet to decide on the safety and effectiveness of the Moderna booster shot.

What Americans are saying

Getty Images

A recent Reuters/Ipsos poll shows that a vast majority – 76% – of Americans that have been partially or fully vaccinated want a booster jab.

Many Americans, however, say they are confused about who can receive the boosters and what the benefits are.

“Of course, I’m confused. On one day the White House said that they’d give boosters to everyone. It turns out only some people can get them. I still don’t know who decides,” said Virginia resident David Williams. “It seems to me there’s been a lot of contradictions.”

Others have reported being confused by the difference between the term “booster” and “third jab” and whether they mean the same thing or not.

Doctors typically use the term “booster” when referencing additional doses being given after the protection provided by the original vaccine begins to decrease. A third dose, on the other hand, typically refers to additional doses being given to immunocompromised people. Over the course of the pandemic, however, the terms have been used interchangeably in many instances.

“I wasn’t confused until recently when I began seeing the language of ‘third or booster’,” said Nevada resident Doris Rueda. “I think so many people think they are one and the same, but I think knowing there is a difference is important, especially [if one has] immunocompromised relatives.”

Greg Samuel, who lives in Washington DC, said that while he isn’t confused about boosters, he doesn’t expect a smooth roll-out process.

“The guidance I have received from my healthcare provider has been decent,” he said. “I think most people will know how this game works after the first go-round, but since that system was a huge disaster…I expect another disaster rollout to follow.”

Among unvaccinated Americans, a recent poll from the Kaiser Family Foundation found that 71% believe boosters are a sign that vaccines are not working.

“I do not see a need for boosters if the vaccine doesn’t work like it’s supposed to,” said Jenson Bland, a 21-year-old unvaccinated resident of Georgia. “I only see it as a money-maker.”

What scientists are saying

Getty Images

Dr Priscilla Hanudel, a Los Angeles-based emergency doctor, told the BBC she isn’t surprised that people are confused.

“There’s so many different steps in the process. I think it can be a little hard for people to understand until final approvals are in,” she said.

Currently, Dr Hanudel recommends that immunocompromised people “definitely” receive an additional dose of the vaccine. She believes that it is likely that boosters will be authorised for the general public as immunity wanes.

“I think it’s going to look similar to the flu shot once a year,” she said. “Whether that’s a booster or thought of as just another annual shot, I think it’s going to happen forever for everyone eventually.”

Julia Raifman, an assistant professor at Boston University’s School of Public Health who tracks Covid-19 policies, said that the debate over boosters is a sign that the US needs to “reset” pandemic policymaking.

“Strong, clear, well thought out and vetted messages from national leaders is key to communicating in a crisis,” she said. “We didn’t see a well-developed policy decision with boosters or with the May guidance that people remove masks. In both cases it really undercut public health.”

Dr Monica Gandhi, an infectious diseases physician and professor at the University of California San Francisco, said that while she believes that immunocompromised people and at-risk frontline workers should get additional jabs, other vaccine doses should be sent abroad to countries with low vaccination rates.

“There’s a moral and ethical obligation. We’ve had these vaccines for 10 months and we managed to only get 4% in the hands of low-income countries,” she said.

The World Health Organization has called on wealthier nations to hold off on widespread rollouts of booster shots until vaccination rates go up in lesser developed countries. In September, WHO Director-General Tedros Adhanom Ghebreyesus said it was “really not right” to give boosters to “healthy populations”.

Dr Gandhi added: “From a public health perspective, no one is safe from the emergence of other variants unless we get transmission down worldwide.”

Adblock test (Why?)



Source link

Continue Reading

Business

Japan’s SoftBank returns to profit after gains at Vision Fund and other investments

Published

 on

 

TOKYO (AP) — Japanese technology group SoftBank swung back to profitability in the July-September quarter, boosted by positive results in its Vision Fund investments.

Tokyo-based SoftBank Group Corp. reported Tuesday a fiscal second quarter profit of nearly 1.18 trillion yen ($7.7 billion), compared with a 931 billion yen loss in the year-earlier period.

Quarterly sales edged up about 6% to nearly 1.77 trillion yen ($11.5 billion).

SoftBank credited income from royalties and licensing related to its holdings in Arm, a computer chip-designing company, whose business spans smartphones, data centers, networking equipment, automotive, consumer electronic devices, and AI applications.

The results were also helped by the absence of losses related to SoftBank’s investment in office-space sharing venture WeWork, which hit the previous fiscal year.

WeWork, which filed for Chapter 11 bankruptcy protection in 2023, emerged from Chapter 11 in June.

SoftBank has benefitted in recent months from rising share prices in some investment, such as U.S.-based e-commerce company Coupang, Chinese mobility provider DiDi Global and Bytedance, the Chinese developer of TikTok.

SoftBank’s financial results tend to swing wildly, partly because of its sprawling investment portfolio that includes search engine Yahoo, Chinese retailer Alibaba, and artificial intelligence company Nvidia.

SoftBank makes investments in a variety of companies that it groups together in a series of Vision Funds.

The company’s founder, Masayoshi Son, is a pioneer in technology investment in Japan. SoftBank Group does not give earnings forecasts.

___

Yuri Kageyama is on X:

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Trump campaign promises unlikely to harm entrepreneurship: Shopify CFO

Published

 on

 

Shopify Inc. executives brushed off concerns that incoming U.S. President Donald Trump will be a major detriment to many of the company’s merchants.

“There’s nothing in what we’ve heard from Trump, nor would there have been anything from (Democratic candidate) Kamala (Harris), which we think impacts the overall state of new business formation and entrepreneurship,” Shopify’s chief financial officer Jeff Hoffmeister told analysts on a call Tuesday.

“We still feel really good about all the merchants out there, all the entrepreneurs that want to start new businesses and that’s obviously not going to change with the administration.”

Hoffmeister’s comments come a week after Trump, a Republican businessman, trounced Harris in an election that will soon return him to the Oval Office.

On the campaign trail, he threatened to impose tariffs of 60 per cent on imports from China and roughly 10 per cent to 20 per cent on goods from all other countries.

If the president-elect makes good on the promise, many worry the cost of operating will soar for companies, including customers of Shopify, which sells e-commerce software to small businesses but also brands as big as Kylie Cosmetics and Victoria’s Secret.

These merchants may feel they have no choice but to pass on the increases to customers, perhaps sparking more inflation.

If Trump’s tariffs do come to fruition, Shopify’s president Harley Finkelstein pointed out China is “not a huge area” for Shopify.

However, “we can’t anticipate what every presidential administration is going to do,” he cautioned.

He likened the uncertainty facing the business community to the COVID-19 pandemic where Shopify had to help companies migrate online.

“Our job is no matter what comes the way of our merchants, we provide them with tools and service and support for them to navigate it really well,” he said.

Finkelstein was questioned about the forthcoming U.S. leadership change on a call meant to delve into Shopify’s latest earnings, which sent shares soaring 27 per cent to $158.63 shortly after Tuesday’s market open.

The Ottawa-based company, which keeps its books in U.S. dollars, reported US$828 million in net income for its third quarter, up from US$718 million in the same quarter last year, as its revenue rose 26 per cent.

Revenue for the period ended Sept. 30 totalled US$2.16 billion, up from US$1.71 billion a year earlier.

Subscription solutions revenue reached US$610 million, up from US$486 million in the same quarter last year.

Merchant solutions revenue amounted to US$1.55 billion, up from US$1.23 billion.

Shopify’s net income excluding the impact of equity investments totalled US$344 million for the quarter, up from US$173 million in the same quarter last year.

Daniel Chan, a TD Cowen analyst, said the results show Shopify has a leadership position in the e-commerce world and “a continued ability to gain market share.”

In its outlook for its fourth quarter of 2024, the company said it expects revenue to grow at a mid-to-high-twenties percentage rate on a year-over-year basis.

“Q4 guidance suggests Shopify will finish the year strong, with better-than-expected revenue growth and operating margin,” Chan pointed out in a note to investors.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:SHOP)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

RioCan cuts nearly 10 per cent staff in efficiency push as condo market slows

Published

 on

 

TORONTO – RioCan Real Estate Investment Trust says it has cut almost 10 per cent of its staff as it deals with a slowdown in the condo market and overall pushes for greater efficiency.

The company says the cuts, which amount to around 60 employees based on its last annual filing, will mean about $9 million in restructuring charges and should translate to about $8 million in annualized cash savings.

The job cuts come as RioCan and others scale back condo development plans as the market softens, but chief executive Jonathan Gitlin says the reductions were from a companywide efficiency effort.

RioCan says it doesn’t plan to start any new construction of mixed-use properties this year and well into 2025 as it adjusts to the shifting market demand.

The company reported a net income of $96.9 million in the third quarter, up from a loss of $73.5 million last year, as it saw a $159 million boost from a favourable change in the fair value of investment properties.

RioCan reported what it says is a record-breaking 97.8 per cent occupancy rate in the quarter including retail committed occupancy of 98.6 per cent.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:REI.UN)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version